Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (DUAL™ I)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01336023
First received: April 13, 2011
Last updated: January 6, 2014
Last verified: January 2014
  Purpose

This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Mean change from baseline in HbA1c (glycosylated haemoglobin) at week 26 [ Time Frame: Week 0, week 26 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean change from baseline in body weight at week 26 [ Time Frame: Week 0, Week 26 ] [ Designated as safety issue: No ]
  • Number of hypoglycaemic episodes [ Time Frame: Weeks 0-26 ] [ Designated as safety issue: No ]
  • Change from baseline in incremental area under the curve 0-4h (iAUC0-4h) derived from the glucose concentration profile during meal test [ Time Frame: Week 0, Week 26 ] [ Designated as safety issue: No ]
  • Mean actual daily insulin dose [ Time Frame: Week 26 ] [ Designated as safety issue: No ]

Enrollment: 1663
Study Start Date: May 2011
Study Completion Date: November 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IDeg Drug: insulin degludec
Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
Experimental: IDegLira Drug: insulin degludec/liraglutide
Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
Experimental: Lira Drug: liraglutide
Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with type 2 diabetes
  • HbA1c 7.0-10.0 % (both inclusive) with the aim of a median HbA1c of 8.3%. Accordingly, when approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c of below or equal to 8.3%, or when approximately 50% of the randomised subjects have a HbA1c of below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%
  • Male or female, age 18 years or above (Taiwan: 20 years or above for a site 653 in Taiwan: Taichung Veterans General Hospital)
  • Subjects on stable dose of 1-2 OADs (metformin [at least 1500 mg or max tolerated dose] or metformin [at least 1500 mg or max tolerated dose] + pioglitazone [at least 30 mg]) for at least 90 days prior to screening
  • Body Mass Index (BMI) maximum 40 kg/m^2

Exclusion Criteria:

  • Treatment with insulin (except for short-term treatment due to intercurrent illness at the discretion of the Investigator)
  • Treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (eg exenatide, liraglutide), sulphonylurea or dipeptidyl peptidase 4 (DPP-4) inhibitors within 90 days prior to trial
  • Impaired liver function, defined as alanine aminotransferese (ALAT) at least 2.5 times Upper Normal Range (UNR) (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
  • Impaired renal function defined as serum-creatinine at least 133 mcmol/l (at least 1.5 mg/dl) for males and at least 125 mcmol/l (at least 1.4) for females, or as allowed according to local contraindications for metformin (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
  • Screening calcitonin at least 50 ng/L
  • Subjects with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months and planned coronary, carotid or peripheral artery revascularisation procedures
  • Severe uncontrolled treated or untreated hypertension (systolic blood pressure at least 180 mm Hg or diastolic blood pressure at least 100 mm Hg)
  • Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01336023

  Hide Study Locations
Locations
United States, Alabama
Novo Nordisk Clinical Trial Call Center
Birmingham, Alabama, United States, 35216
United States, California
Novo Nordisk Clinical Trial Call Center
Anaheim, California, United States, 92801
Novo Nordisk Clinical Trial Call Center
Chino, California, United States, 91710
Novo Nordisk Clinical Trial Call Center
Concord, California, United States, 94520
Novo Nordisk Clinical Trial Call Center
Encino, California, United States, 91436
Novo Nordisk Clinical Trial Call Center
Fair Oaks, California, United States, 95628
Novo Nordisk Clinical Trial Call Center
Fresno, California, United States, 93726
Novo Nordisk Clinical Trial Call Center
Greenbrae, California, United States, 94904
Novo Nordisk Clinical Trial Call Center
La Jolla, California, United States, 92037
Novo Nordisk Clinical Trial Call Center
Long Beach, California, United States, 90807
Novo Nordisk Clinical Trial Call Center
Los Angeles, California, United States, 90057
Novo Nordisk Clinical Trial Call Center
Monterey, California, United States, 93940
Novo Nordisk Clinical Trial Call Center
Orange, California, United States, 92868
Novo Nordisk Clinical Trial Call Center
Palm Springs, California, United States, 92262-6972
Novo Nordisk Clinical Trial Call Center
Poway, California, United States, 92064
Novo Nordisk Clinical Trial Call Center
San Diego, California, United States, 92117
Novo Nordisk Clinical Trial Call Center
San Diego, California, United States, 92161-0002
Novo Nordisk Clinical Trial Call Center
San Diego, California, United States, 92111
Novo Nordisk Clinical Trial Call Center
San Mateo, California, United States, 94401
Novo Nordisk Clinical Trial Call Center
Santa Barbara, California, United States, 93105
Novo Nordisk Clinical Trial Call Center
Tustin, California, United States, 92780
Novo Nordisk Clinical Trial Call Center
Valencia, California, United States, 91355
Novo Nordisk Clinical Trial Call Center
Walnut Creek, California, United States, 94598
United States, Colorado
Novo Nordisk Clinical Trial Call Center
Colorado Springs, Colorado, United States, 80910
Novo Nordisk Clinical Trial Call Center
Denver, Colorado, United States, 80209
Novo Nordisk Clinical Trial Call Center
Golden, Colorado, United States, 80401
United States, Connecticut
Novo Nordisk Clinical Trial Call Center
Waterbury, Connecticut, United States, 06708
United States, Delaware
Novo Nordisk Clinical Trial Call Center
Newark, Delaware, United States, 19713
United States, Florida
Novo Nordisk Clinical Trial Call Center
Clearwater, Florida, United States, 33765
Novo Nordisk Clinical Trial Call Center
Fort Lauderdale, Florida, United States, 33316-2521
Novo Nordisk Clinical Trial Call Center
Hialeah, Florida, United States, 33012
Novo Nordisk Clinical Trial Call Center
Kissimmee, Florida, United States, 34741
Novo Nordisk Clinical Trial Call Center
Melbourne, Florida, United States, 32935
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33135
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33156
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33135-1687
Novo Nordisk Clinical Trial Call Center
Orange Park, Florida, United States, 32073
Novo Nordisk Clinical Trial Call Center
Orlando, Florida, United States, 32804
Novo Nordisk Clinical Trial Call Center
Pembroke Pines, Florida, United States, 33027
Novo Nordisk Clinical Trial Call Center
Tampa, Florida, United States, 33603
United States, Georgia
Novo Nordisk Clinical Trial Call Center
Atlanta, Georgia, United States, 30318
Novo Nordisk Clinical Trial Call Center
Columbus, Georgia, United States, 31909-1692
Novo Nordisk Clinical Trial Call Center
Conyers, Georgia, United States, 30094-5965
Novo Nordisk Clinical Trial Call Center
Decatur, Georgia, United States, 30035
Novo Nordisk Clinical Trial Call Center
Lawrenceville, Georgia, United States, 30046
Novo Nordisk Clinical Trial Call Center
Roswell, Georgia, United States, 30076-2126
United States, Idaho
Novo Nordisk Clinical Trial Call Center
Meridian, Idaho, United States, 83646
Novo Nordisk Clinical Trial Call Center
Nampa, Idaho, United States, 83686-6011
United States, Illinois
Novo Nordisk Clinical Trial Call Center
Chicago, Illinois, United States, 60607
Novo Nordisk Clinical Trial Call Center
Gurnee, Illinois, United States, 60031
Novo Nordisk Clinical Trial Call Center
O Fallon, Illinois, United States, 62246
United States, Indiana
Novo Nordisk Clinical Trial Call Center
Avon, Indiana, United States, 46123
Novo Nordisk Clinical Trial Call Center
Fishers, Indiana, United States, 46038-1862
Novo Nordisk Clinical Trial Call Center
Franklin, Indiana, United States, 46131-9121
Novo Nordisk Clinical Trial Call Center
Indianapolis, Indiana, United States, 46254
Novo Nordisk Clinical Trial Call Center
Michigan City, Indiana, United States, 46383
Novo Nordisk Clinical Trial Call Center
Muncie, Indiana, United States, 47304
United States, Kentucky
Novo Nordisk Clinical Trial Call Center
Crestview Hills, Kentucky, United States, 41017-3464
Novo Nordisk Clinical Trial Call Center
Lexington, Kentucky, United States, 40503
United States, Louisiana
Novo Nordisk Clinical Trial Call Center
Metairie, Louisiana, United States, 70006-2930
Novo Nordisk Clinical Trial Call Center
Metairie, Louisiana, United States, 70006
United States, Maryland
Novo Nordisk Clinical Trial Call Center
Hyattsville, Maryland, United States, 20782
Novo Nordisk Clinical Trial Call Center
Rockville, Maryland, United States, 20852
United States, Michigan
Novo Nordisk Clinical Trial Call Center
Buckley, Michigan, United States, 49620
Novo Nordisk Clinical Trial Call Center
Southfield, Michigan, United States, 48075
Novo Nordisk Clinical Trial Call Center
Southfield, Michigan, United States, 48034-7661
Novo Nordisk Clinical Trial Call Center
Troy, Michigan, United States, 48098
United States, Missouri
Novo Nordisk Clinical Trial Call Center
Chesterfield, Missouri, United States, 63017
Novo Nordisk Clinical Trial Call Center
St. Charles, Missouri, United States, 63303
United States, Nevada
Novo Nordisk Clinical Trial Call Center
Henderson, Nevada, United States, 89052-2649
Novo Nordisk Clinical Trial Call Center
Las Vegas, Nevada, United States, 89106
United States, New Hampshire
Novo Nordisk Clinical Trial Call Center
Nashua, New Hampshire, United States, 03063
United States, New Jersey
Novo Nordisk Clinical Trial Call Center
Toms River, New Jersey, United States, 08753-2975
Novo Nordisk Clinical Trial Call Center
Toms River, New Jersey, United States, 08755-8050
United States, New York
Novo Nordisk Clinical Trial Call Center
Albany, New York, United States, 12206
Novo Nordisk Clinical Trial Call Center
Bronx, New York, United States, 10461
Novo Nordisk Clinical Trial Call Center
West Seneca, New York, United States, 14224
United States, North Carolina
Novo Nordisk Clinical Trial Call Center
Asheboro, North Carolina, United States, 27203
Novo Nordisk Clinical Trial Call Center
Asheville, North Carolina, United States, 28803
Novo Nordisk Clinical Trial Call Center
Burlington, North Carolina, United States, 27215-8700
Novo Nordisk Clinical Trial Call Center
Charlotte, North Carolina, United States, 28277
Novo Nordisk Clinical Trial Call Center
Durham, North Carolina, United States, 27713
Novo Nordisk Clinical Trial Call Center
Greensboro, North Carolina, United States, 27408
Novo Nordisk Clinical Trial Call Center
Morehead City, North Carolina, United States, 28557
Novo Nordisk Clinical Trial Call Center
Shelby, North Carolina, United States, 28152
Novo Nordisk Clinical Trial Call Center
Statesville, North Carolina, United States, 28625-1916
Novo Nordisk Clinical Trial Call Center
Winston Salem, North Carolina, United States, 27103
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Canton, Ohio, United States, 44718
Novo Nordisk Clinical Trial Call Center
Cincinnati, Ohio, United States, 45242
Novo Nordisk Clinical Trial Call Center
Cincinnati, Ohio, United States, 45242-4494
Novo Nordisk Clinical Trial Call Center
Cincinnati, Ohio, United States, 45224
Novo Nordisk Clinical Trial Call Center
Columbus, Ohio, United States, 43207-1230
Novo Nordisk Clinical Trial Call Center
Franklin, Ohio, United States, 45005
Novo Nordisk Clinical Trial Call Center
Kettering, Ohio, United States, 45429
Novo Nordisk Clinical Trial Call Center
Mason, Ohio, United States, 45040-6815
Novo Nordisk Clinical Trial Call Center
Maumee, Ohio, United States, 43537
United States, Oklahoma
Novo Nordisk Clinical Trial Call Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Novo Nordisk Clinical Trial Call Center
Beaver, Pennsylvania, United States, 15009
Novo Nordisk Clinical Trial Call Center
Bridgeville, Pennsylvania, United States, 15017
Novo Nordisk Clinical Trial Call Center
Norristown, Pennsylvania, United States, 19401
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19152
Novo Nordisk Clinical Trial Call Center
Philadelphia, Pennsylvania, United States, 19107
Novo Nordisk Clinical Trial Call Center
Pittsburgh, Pennsylvania, United States, 15224-2215
United States, Rhode Island
Novo Nordisk Clinical Trial Call Center
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Novo Nordisk Clinical Trial Call Center
Columbia, South Carolina, United States, 29201-2970
Novo Nordisk Clinical Trial Call Center
Greer, South Carolina, United States, 29651
Novo Nordisk Clinical Trial Call Center
Pelzer, South Carolina, United States, 29669
Novo Nordisk Clinical Trial Call Center
Simpsonville, South Carolina, United States, 29681
Novo Nordisk Clinical Trial Call Center
Spartanburg, South Carolina, United States, 29303
Novo Nordisk Clinical Trial Call Center
Taylors, South Carolina, United States, 29687
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Chattanooga, Tennessee, United States, 37411
Novo Nordisk Clinical Trial Call Center
Chattanooga, Tennessee, United States, 37404
Novo Nordisk Clinical Trial Call Center
Kingsport, Tennessee, United States, 37660
United States, Texas
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75230
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75390-8858
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75246
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75251
Novo Nordisk Clinical Trial Call Center
Fort Worth, Texas, United States, 76113
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77095
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77074
Novo Nordisk Clinical Trial Call Center
Irving, Texas, United States, 75061-2210
Novo Nordisk Clinical Trial Call Center
Killeen, Texas, United States, 76543-5600
Novo Nordisk Clinical Trial Call Center
Lubbock, Texas, United States, 79423
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78215
Novo Nordisk Clinical Trial Call Center
San Antonio, Texas, United States, 78224
Novo Nordisk Clinical Trial Call Center
Sugarland, Texas, United States, 77478
United States, Utah
Novo Nordisk Clinical Trial Call Center
Ogden, Utah, United States, 84403
Novo Nordisk Clinical Trial Call Center
Salt Lake City, Utah, United States, 84107
Novo Nordisk Clinical Trial Call Center
St. George, Utah, United States, 84790
United States, Virginia
Novo Nordisk Clinical Trial Call Center
Burke, Virginia, United States, 22015
Novo Nordisk Clinical Trial Call Center
Manassas, Virginia, United States, 20110
Novo Nordisk Clinical Trial Call Center
Norfolk, Virginia, United States, 23502
Novo Nordisk Clinical Trial Call Center
Virginia Beach, Virginia, United States, 23462
United States, Washington
Novo Nordisk Clinical Trial Call Center
Spokane, Washington, United States, 99208
United States, Wisconsin
Novo Nordisk Clinical Trial Call Center
Milwaukee, Wisconsin, United States, 53209
Australia, New South Wales
Penrith, New South Wales, Australia, 2751
Canada, Alberta
Edmonton, Alberta, Canada, T5J 3N4
Finland
Oulu, Finland, 90100
Germany
Rehburg-Loccum, Germany, 31547
Hungary
Eger, Hungary, 3300
India
Cochin, Kerala, India, 695010
Ireland
Dublin, Ireland, DUBLIN 7
Italy
Palermo, Italy, 90127
Malaysia
Cheras, Malaysia, 56000
Mexico
Guadalajara, Jalisco, Mexico, 44600
Puerto Rico
Novo Nordisk Clinical Trial Call Center
San Juan, Puerto Rico, 00921
Russian Federation
Voronezh, Russian Federation, 394018
Singapore
Singapore, Singapore, 308433
Slovakia
Moldava nad Bodvou, Slovakia, 045 01
South Africa
Port Elizabeth, Eastern Cape, South Africa, 6014
Spain
Partida de Bacarot, Spain, 03114
Taiwan
Taichung City, Taiwan, 407
Thailand
Bangkok, Thailand, 10400
United Kingdom
Bury St Edmunds, United Kingdom, IP33 2QZ
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
No publications provided

Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01336023     History of Changes
Other Study ID Numbers: NN9068-3697, U1111-1119-1174, 2010-021560-15
Study First Received: April 13, 2011
Last Updated: January 6, 2014
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Canada: Health Canada
Finland: Finnish Medicines Agency Fimea
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Ministry of Health, Social and Family Affairs
India: Ministry of Health
Ireland: Irish Medicines Board
Italy: Ministry of Health
Malaysia: Ministry of Health
Mexico: National Institute of Public Health, Health Secretariat
Russia: Federal Service for Control of Health Care and Social Development
Singapore: Health Sciences Authority
Slovakia: State Institute for Drug Control
South Africa: Medicines Control Council
Spain: Ministry of Health
Taiwan: Department of Health
Thailand: Ministry of Public Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Glucagon-Like Peptide 1
Physiological Effects of Drugs
Pharmacologic Actions
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on July 20, 2014